nach oben

Erschienen in:

01.03.2011 | Original Paper

Clinical significance of the ratio between the alpha 2 plasmin inhibitor–plasmin complex and the thrombin–antithrombin complex in advanced non-small cell lung cancer

verfasst von: Katsuhiro Masago, Shiro Fujita, Tadashi Mio, Yosuke Togashi, Young Hak Kim, Yukimasa Hatachi, Akiko Fukuhara, Kaoru Irisa, Yuichi Sakamori, Michiaki Mishima

Erschienen in: Medical Oncology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

The aims of this study are to: (a) confirm the prognostic significance of the procoagulant molecules D dimer, thrombin–antithrombin complex (TAT), and plasmin-α2–plasmin inhibitor complex (PIC); (b) to evaluate hemostatic activation in patients with advanced non-small cell lung cancer (NSCLC); and (c) to delineate the relationships between markers of hemostasis and other clinical characteristics. In this study, a low PIC/TAT ratio and poor PS were significant independent negative prognostic factors for survival in patients with advanced NSCLC. The PIC/TAT ratio may become a surrogate marker for treatment with anticoagulants in the future.

Antoniou D, Pavlakou G, Stathopoulos GP, et al. Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer. 2006;53:205–10.PubMedCrossRef

Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer. 2003;97:3044–52.PubMedCrossRef

Gabazza EC, Taguchi O, Yamakami T, et al. Evaluating prethrombotic state in lung cancer using molecular markers. Chest. 1993;103:196–200.PubMedCrossRef

Unsal E, Atalay F, Atikcan S, et al. Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med. 2004;98:93–8.PubMedCrossRef

Gordon SG. Cancer cell procoagulants and their role in malignant disease. Semin Thromb Hemost. 1992;18:424–33.PubMedCrossRef

Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost. 1992;18:353–72.PubMedCrossRef

Taguchi O, Gabazza EC, Yoshida M, et al. High plasma level of plasmin-alpha 2-plasmin inhibitor complex is predictor of poor prognosis in patients with lung cancer. Clin Chim Acta. 1996;244:69–81.PubMedCrossRef

Seitz R, Heidtmann HH, Wolf M, et al. Prognostic impact of an activation of coagulation in lung cancer. Ann Oncol. 1997;8:781–4.PubMedCrossRef

Watine J. Prognostic impact of an activation of coagulation in lung cancer. Ann Oncol. 1998;9:1255–6.PubMedCrossRef

10.

Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin–antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost. 1988;59:101–6.PubMed

11.

Mimuro J, Koike Y, Sumi Y, et al. Monoclonal antibodies to discrete regions in alpha 2-plasmin inhibitor. Blood. 1987;69:446–53.PubMed

12.

Goad KE, Gralnick HR. Coagulation disorders in cancer. Hematol Oncol Clin North Am. 1996;10:457–84.PubMedCrossRef

13.

Altiay G, Ciftci A, Demir M, et al. High plasma D-dimer level is associated with decreased survival in patients with lung cancer. Clin Oncol (R Coll Radiol). 2007;19:494–8.

14.

Buccheri G, Ferrigno D, Ginardi C, et al. Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer. 1997;33:50–5.PubMedCrossRef

15.

Langer F, Spath B, Haubold K, et al. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation. Ann Hematol. 2008;87:451–7.PubMedCrossRef

16.

Pavey SJ, Hawson GA, Marsh NA. Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis. 2001;12:51–8.PubMedCrossRef

17.

Taguchi O, Gabazza EC, Yasui H, et al. Prognostic significance of plasma D-dimer levels in patients with lung cancer. Thorax. 1997;52:563–5.PubMedCrossRef

18.

Kwaan HC, Keer HN. Fibrinolysis and cancer. Semin Thromb Hemost. 1990;16:230–5.PubMedCrossRef

19.

Alessi MC, Chomiki N, Berthier R, et al. Detection of plasminogen activator inhibitor-1 (PAI-1) mRNA in human megakaryocytes by in situ hybridization. Thromb Haemost. 1994;72:931–6.PubMed

20.

Madoiwa S, Komatsu N, Mimuro J, et al. Developmental expression of plasminogen activator inhibitor-1 associated with thrombopoietin-dependent megakaryocytic differentiation. Blood. 1999;94:475–82.PubMed

21.

Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650–9.PubMedCrossRef

22.

Levine MN, Lee AY, Kakkar AK. From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. J Thromb Haemost. 2003;1:1456–63.PubMedCrossRef

23.

Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev. 2001;53:93–105.PubMed

24.

Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anticoagulation trial. N Engl J Med. 2000;342:1953–8.PubMedCrossRef

25.

Akl EA, Muti P, Schunemann HJ. Anticoagulation in patients with cancer: an overview of reviews. Pol Arch Med Wewn. 2008;118:183–93.PubMed

Titel: Clinical significance of the ratio between the alpha 2 plasmin inhibitor–plasmin complex and the thrombin–antithrombin complex in advanced non-small cell lung cancer
verfasst von: Katsuhiro Masago
Shiro Fujita
Tadashi Mio
Yosuke Togashi
Young Hak Kim
Yukimasa Hatachi
Akiko Fukuhara
Kaoru Irisa
Yuichi Sakamori
Michiaki Mishima
Publikationsdatum: 01.03.2011
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 1/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-010-9454-y

Neu im Fachgebiet Onkologie

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Clinical significance of the ratio between the alpha 2 plasmin inhibitor–plasmin complex and the thrombin–antithrombin complex in advanced non-small cell lung cancer

Abstract

Neu im Fachgebiet Onkologie

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

AML: Komplettremission kein Muss für erfolgreiche Stammzelltransplantation

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Investigation of human papillomavirus DNA in colorectal carcinomas and adenomas

Prognostic significance of telomerase activity and some tumor markers in non-small cell lung cancer

Adenovirus-mediated transfer of siRNA against basic fibroblast growth factor mRNA enhances the sensitivity of glioblastoma cells to chemotherapy

Prognostic value of β-catenin, c-myc, and cyclin D1 expressions in patients with esophageal squamous cell carcinoma

Clear cell adenocarcinoma of the uterine cervix in a young pregnant woman: a case report with immunohistochemical study

Activation of JAK/STAT signal pathway predicts poor prognosis of patients with gliomas

Neu im Fachgebiet Onkologie

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

AML: Komplettremission kein Muss für erfolgreiche Stammzelltransplantation

Update Onkologie